Hefei Yuan biological "plant-derived recombinant human serum albumin" approved for listing.

The official website of the NMPA shows that Hesen Bio's plant-derived recombinant human serum albumin has been approved for listing, used for the treatment of hypoalbuminemia in patients with cirrhosis. It was previously granted priority review by the CDE in August 2024.